{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:02:38Z","timestamp":1778637758202,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Sphingosine-1-phosphate (S1P) receptor modulators, regulating the S1P\/S1PR pathway, lead to lymphocyte sequestration in lymphoid organs, which results in peripheral lymphopenia. This study evaluates the degree of lymphopenia induced by S1P modulators in people with Multiple Sclerosis (MS): Ozanimod, Siponimod, Ponesimod, and Fingolimod.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective multicenter study across thirteen MS centers in Italy, including 191 MS patients (mean age 46.4\u00a0years; 61.3% women). Of these, 28.8% received Siponimod, 26.2% Ozanimod, 24.1% Fingolimod, and 20.9% Ponesimod. Lymphocyte counts were measured at baseline (T0), one month (T1), three months (T3), and six months (T6) post-treatment. Lymphopenia grades range from 0 (\u2265\u20091.0\u2009\u00d7\u200910^9 cells\/L) to 4 (&lt;\u20090.2\u2009\u00d7\u200910^9 cells\/L), according to Common Terminology Criteria for Adverse Events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At T1, Ozanimod showed a significantly higher mean lymphocyte count than Siponimod and Fingolimod (p\u2009&lt;\u20090.001), Ponesimod higher mean lymphocyte count than Siponimod (p\u2009=\u20090.006). The differences persisted between Ozanimod than Siponimod and Fingolimod at T3 (p\u2009=\u20090.01 and p\u2009=\u20090.04), and between Ponesimod and Siponimod at T6 (p\u2009=\u20090.03). Severe lymphopenia cases were significantly higher in Siponimod than in Ponesimod and Ozanimod, at T1 (p\u2009=\u20090.001 and p\u2009=\u20090.0001). The differences remained significant between Ozanimod and Siponimod, at T3 (p\u2009=\u20090.001), and between Ponesimod and Siponimod, Fingolimod and Ozanimod, at T6 (p\u2009=\u20090.001). Grade 4 lymphopenia was observed in Ozanimod and Siponimod at T3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This is the first real-world, head-to-head observational study comparing lymphopenia among different S1P modulators. Our results might assist in therapy choice depending on patients baseline hematological characteristics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-13300-z","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:12:42Z","timestamp":1754496762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study"],"prefix":"10.1007","volume":"272","author":[{"given":"Giorgia Teresa","family":"Maniscalco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Sparaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Di Gregorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Cafasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Iodice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bellantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Zanghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Sinisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Busillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Scarano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Lavorgna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Di Battista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Di Giulio Cesare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Lus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Cassano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola Sofia","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmarco","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Andreone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-9720","authenticated-orcid":false,"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"13300_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nri2974","volume":"11","author":"S Spiegel","year":"2011","unstructured":"Spiegel S, Milstien S (2011) The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 11:403\u2013415","journal-title":"Nat Rev Immunol"},{"key":"13300_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1146\/annurev-immunol-081519-083952","volume":"38","author":"AAL Baeyens","year":"2020","unstructured":"Baeyens AAL, Schwab SR (2020) Finding a way out: S1P signaling and immune cell migration. Annu Rev Immunol 38:759\u2013784","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"13300_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387\u2013401","journal-title":"N Engl J Med"},{"issue":"5","key":"13300_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402\u2013415","journal-title":"N Engl J Med"},{"issue":"10127","key":"13300_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, BarOr A, Cree BAC, Fox RJ, Giovannoni G, Gold R et al (2018) EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double blind, randomised, phase 3 study. Lancet. 391(10127):1263\u20131273","journal-title":"Lancet."},{"issue":"11","key":"13300_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdov\u00e1 E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L (2019) RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 18(11):1021\u20131033","journal-title":"Lancet Neurol."},{"issue":"11","key":"13300_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdov\u00e1 E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 18(11):1009\u20131020","journal-title":"Lancet Neurol"},{"issue":"5","key":"13300_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdov\u00e1 EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D\u2019Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T (2021) Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol 78(5):558\u2013567","journal-title":"JAMA Neurol"},{"key":"13300_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11910-011-0216-9","volume":"11","author":"M Mehling","year":"2011","unstructured":"Mehling M, Kappos L, Derfuss T (2011) Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep 11:492\u2013497","journal-title":"Curr Neurol Neurosci Rep"},{"key":"13300_CR10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","volume":"19","author":"T Derfuss","year":"2020","unstructured":"Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L (2020) Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol 19:336\u2013347","journal-title":"Lancet Neurol"},{"key":"13300_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-021-01523-z","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A (2021) Ponesimod: first approval. Drugs 81:957\u2013962","journal-title":"Drugs"},{"issue":"2","key":"13300_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162","journal-title":"Lancet Neurol"},{"key":"13300_CR13","unstructured":"U.S. Department of health and human services: Common Terminology Criteria for Adverse Events (CTCAE) Version5.0 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"13300_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.msard.2017.11.018","volume":"19","author":"YD Fragoso","year":"2018","unstructured":"Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S et al (2018) Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Mult Scler Relat Disord 19:105-108.3","journal-title":"Mult Scler Relat Disord"},{"key":"13300_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-020-00714-8","volume":"34","author":"G Boffa","year":"2020","unstructured":"Boffa G, Bruschi N, Cellerino M, Lapucci C, Novi G, Sbragia E et al (2020) Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population. CNS Drugs 34:425\u2013432","journal-title":"CNS Drugs"},{"issue":"1","key":"13300_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","volume":"72","author":"AM Arvin","year":"2015","unstructured":"Arvin AM, Wolinsky JS, Kappos L et al (2015) Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 72(1):31\u201339","journal-title":"JAMA Neurol"},{"key":"13300_CR17","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1212\/WNL.0000000000001049","volume":"83","author":"C Warnke","year":"2014","unstructured":"Warnke C, Dehmel T, Ramanujam R et al (2014) Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology 83:2153\u20132157","journal-title":"Neurology"},{"key":"13300_CR18","first-page":"61","volume":"12","author":"S Ruggieri","year":"2022","unstructured":"Ruggieri S, Quartuccio ME, Prosperini L (2022) Ponesimod in the treatment of relapsing forms of multiple sclerosis: an update on the emerging clinical data. Degener Neurol Neuromuscul Dis 12:61\u201373","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"13300_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s43440-025-00725-6","volume":"77","author":"N Balzano","year":"2025","unstructured":"Balzano N, Di Napoli R, Fraenza F et al (2025) Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data. Pharmacol Rep 77:775\u2013788","journal-title":"Pharmacol Rep"},{"issue":"4","key":"13300_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/cer-2019-0169","volume":"9","author":"E Swallow","year":"2020","unstructured":"Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J (2020) Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J Comp Eff Res 9(4):275\u2013285","journal-title":"J Comp Eff Res"},{"issue":"23","key":"13300_CR21","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1212\/WNL.0000000000001049","volume":"83","author":"C Warnke","year":"2014","unstructured":"Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC (2014) Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology 83(23):2153\u20132157","journal-title":"Neurology"},{"issue":"1","key":"13300_CR22","first-page":"205521731875969","volume":"4","author":"R Ohtani","year":"2018","unstructured":"Ohtani R, Mori M, Uchida T, Uzawa A, Masuda H, Liu J, Kuwabara S (2018) Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. Mult Scler J Exp Transl Clin 4(1):2055217318759692","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4\u20135","key":"13300_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/13524585231225711","volume":"30","author":"CG Gilmartin","year":"2024","unstructured":"Gilmartin CG, Hoyle N, Garjani A, Dixon T, Jos H, Paling D, Brownlee W, Tench C, Evangelou N (2024) Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis. Mult Scler 30(4\u20135):600\u2013604","journal-title":"Mult Scler"},{"issue":"11","key":"13300_CR24","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1007\/s10072-021-05546-y","volume":"42","author":"M Sparaco","year":"2021","unstructured":"Sparaco M, Miele G, Bonavita S (2021) Severe lymphopenia switching from Fingolimod to Siponimod. Neurol Sci 42(11):4837\u20134838","journal-title":"Neurol Sci"},{"key":"13300_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105135","volume":"81","author":"D Caliendo","year":"2024","unstructured":"Caliendo D, Grassia MC, Carotenuto A, Petracca M, Lanzillo R, Brescia Morra V, Moccia M (2024) Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia. Mult Scler Relat Disord 81:105135","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13300-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13300-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13300-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:35:49Z","timestamp":1760524549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13300-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13300"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13300-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"559"}}